Fundraising FoxAlgeta
Unicorn exit · $2.9Bacquired by Bayer4 known investors
Find your way into Algeta
Sign up to see every warm intro you have to Algeta
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Algeta team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Bayer AG December 2013 · $2.9B ($2.9 billion (48% premium to pre-announcement share price)) · source ↗
Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.
Investors · 4
Advent Life Scienceslisted by Advent Life SciencesLondon
How we know: Advent Life Sciences's portfolio page · Not right? Tell us
Birk Venturelisted by Birk VentureOslo
How we know: Birk Venture's portfolio page · Not right? Tell us
AbingworthreportedLondon · $15M – $30M
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Algeta do?
- Algeta was a Norwegian oncology company developing alpha-particle radiopharmaceuticals, notably Xofigo (radium-223 dichloride) for bone metastases in prostate cancer.
- Who are Algeta's investors?
- Algeta's investors include Advent Life Sciences, Birk Venture, HealthCap, Abingworth.
- Who acquired Algeta?
- Algeta was acquired by Bayer.